LBA46 SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head &amp; neck squamous cell carcinoma (RMHNSCC) patients (pts) progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy

Nicolas Mach ,T Rordorf,K Gysel,O Vonrohr O Vonrohr,T Brezina,V Saingier,E Fernandez,J.N Grogg,E Charrier,J Renaux,C De Vito C De Vito,V Ancrenaz,M-C Belkouch,M Urwyler,Gabriele Müller ,Rémi Vernet ,Markus Joerger ,Olivier Rubin ,Fabien Courtout ,Olivier Michielin

doi:10.1016/j.annonc.2023.10.040

LBA46 SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head & neck squamous cell carcinoma (RMHNSCC) patients (pts) progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy

Nicolas Mach , T Rordorf + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2023.10.040

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Oct 1, 2023
Citations: 1

#Line Of Systemic Therapy #Neck Squamous Cell Carcinoma + Show 7 more

Abstract
Full-Text PDF
Similar Papers

Abstract

LBA46 SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head & neck squamous cell carcinoma (RMHNSCC) patients (pts) progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy

Full Text